ClinicalTrials.gg
Active, not recruitingNCT05374512Updated May 15, 2026

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

A Phase 3 interventional study of Dato-DXd and Paclitaxel in Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 228 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
644
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing datopotamab deruxtecan in Breast Neoplasms — 8 open to participants now, 14 under way, 6 of them phase 3. datopotamab deruxtecan · Breast Neoplasms.

Enrollment
5th of 14
644 · median 300
Started
2022
with 1 other
Phase 3
6 of 14
2 open now
Primary completion
2025-08
later than 2 of 13 live
Registered
4th of 14
by date
Lead sponsor
7 of 14
AstraZeneca

Among the 14 studies testing datopotamab deruxtecan in Breast Neoplasms, this one is the 5th largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 3, reaches primary completion later than 2 of the 13 other live ones, and was the 4th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 14 studies testing datopotamab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About datopotamab deruxtecan

datopotamab deruxtecan: first FDA approval 2025 (DATROWAY), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing datopotamab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.

Read the detailed description

The primary objectives of the study are to demonstrate superiority of Dato-DXd relative to ICC by assessment of PFS in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy, per BICR and to demonstrate superiority of Dato-DXd relative to ICC by assessment of OS in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.

03

Conditions studied

  • Breast Cancer

Keywords

  • Breast Cancer;
  • PD-1/PD-L1 Therapy;
  • Dato-DXd; DS1062a;
  • TROP2;
  • Triple-negative;
  • Metastatic; Inoperable;
  • Datopotamab deruxtecan;
  • Antibody Drug Conjugate;
  • ADC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age

  1. Participant must be ≥ 18 years at the time of screening. Type of Participant and Disease Characteristics
  2. or cytologically documented locally recurrent inoperable TNBC, which cannot be treated with curative intent, or TNBC. TNBC is defined as:

    • Negative for ER with \< 1% of tumour cells positive for ER on IHC.
    • Negative for progesterone receptor with \< 1% of tumour cells positive for progesterone receptor on IHC.
    • Negative for with 0 or 1+ intensity on IHC or 2+ intensity on IHC and negative by in situ hybridisation per the ASCO-CAP HER2 guideline
  3. No prior chemotherapy or other systemic anti-cancer therapy for metastatic or locally recurrent inoperable breast cancer.
  4. Not a candidate for /PD-L1 inhibitor therapy, defined as:

    • Participants whose tumours are PD-L1-negative, or
    • Participants whose tumours are PD-L1-positive and have:

      1. after prior PD-1/PD-L1 inhibitor therapy for early-stage breast cancer,
      2. comorbidities precluding PD-1/PD-L1 inhibitor therapy, or
      3. no regulatory access to pembrolizumab [participant's country does not have regulatory approval at the time of screening]).
  5. At least 1 not previously irradiated that qualifies as a 1.1 TL at baseline and can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI), and is suitable for accurate repeated measurements.
  6. PS 0 or 1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.
  7. Eligible for one of the chemotherapy options listed as ICC (paclitaxel, nab-paclitaxel, capecitabine, carboplatin, or eribulin), based on DFI and prior taxane exposure, per investigator assessment.
  8. Has had an adequate treatment before Cycle 1 Day 1, defined as:

    • Major surgery: ≥ 3 weeks.
    • Radiation therapy including palliative radiation to chest: ≥ 4 weeks (palliative radiation therapy to other areas ≥ 2 weeks).
    • therapy for central nervous system metastatic disease: > 3 days.
    • Anti cancer therapy including hormonal therapy: ≥ 3 weeks (for small molecule targeted agents: ≥ 2 weeks or 5 half-lives, whichever is longer).
    • Nitrosoureas or mitomycin C: ≥ 6 weeks.
    • Antibody-based anti cancer therapy: ≥ 4 weeks with the exception of receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors (eg, denosumab for the treatment of bone metastases).
    • Immunotherapy (non-antibody-based therapy), retinoid therapy: ≥ 2 weeks or 5 times the terminal elimination half-life of the agent, whichever is longer.
    • Chloroquine/hydroxychloroquine: > 14 days.
  9. Written confirmation of tumour sample needs to be available prior to enrolment and tumour samples should be available prior to randomisation. All participants must have a FFPE metastatic (excluding bone) or locally recurrent inoperable tumour sample (block preferred, or a minimum of 20 freshly cut slides) available, collected ≤ 3 months prior to screening. If neither an adequate FFPE block nor the minimum of 20 slides are available from the most recent , or if a biopsy is not feasible for safety reasons, and this is clearly documented, an archival tumour specimen obtained before the diagnosis of locally recurrent inoperable or metastatic breast cancer may be submitted, pending approval by the Global Study Team.
  10. Participants with a history of previously treated neoplastic spinal cord compression or asymptomatic, stable , who require no treatment with corticosteroids or anticonvulsants may be included in the study, if they are no longer symptomatic and have recovered from acute toxic effects of radiotherapy. A minimum of 2 weeks must have elapsed between the end of radiotherapy and Cycle 1 Day 1. A minimum of 3 days must have elapsed between the end of corticosteroid therapy for central nervous system metastatic disease and Cycle 1 Day 1.
  11. Adequate organ and bone marrow function within 7 days before randomisation as follows:

    • ≥ 9.0 g/dL (red blood cell/plasma transfusion is not allowed within 1 week prior to screening assessment).
    • ≥ 1.5 × 10\^9/L (granulocyte colony stimulating factor administration is not allowed within 1 week prior to screening assessment).
    • count ≥ 100 × 10\^9/L (platelet transfusion is not allowed within 1 week prior to screening assessment).
    • Total (TBL) ≤ 1.5 × (ULN) or \< 3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia).
    • Except in the setting of , (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN for AST/ALT (\< 5 × ULN in participants with liver metastases). See Exclusion Criterion 5 for requirements in the setting of HBV.
    • Calculated CrCL ≥ 30 mL/minute as determined by
  12. Minimum of 12 weeks.

    Sex

  13. Male or female. use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    Reproduction

  14. Negative pregnancy test (serum) for women of .
  15. Female participants must be at least 1 year , surgically sterile, or using at least 1 highly effective form of birth control (a highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly.) Women of childbearing potential who are sexually active with a non sterilised male partner must agree to use at least 1 highly effective method of birth control. They should have been stable on their chosen method of birth control for a minimum of 3 months before Cycle 1 Day 1 and continue for at least 7 months after the last dose. Female participants must refrain from egg cell donation or retrieval for their own use, and breastfeeding from enrolment throughout the study and for at least 7 months after the last dose of study drug. Any non sterilised male partner of a woman of childbearing potential must use a male condom plus spermicide (condom alone in countries where spermicides are not approved) throughout this period.
  16. Male participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile or use an acceptable method of contraception from the time of screening throughout the total duration of the study and the drug washout period (at least 6 months after the last dose of study intervention), in addition to the female partner using a highly effective contraceptive method, to prevent pregnancy in a partner. Male participants must not donate or bank sperm during this same time period. Preservation of sperm should be considered prior to randomisation. Not engaging in heterosexual activity (sexual abstinence) for the duration of the study and drug washout period is an acceptable practice, if this is the preferred usual lifestyle of the participant. Periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.

  17. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  18. Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of sample for optional genetic research that supports Genomic Initiative.

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  1. As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, uncontrolled hypertension, history of allogeneic organ transplant, and active bleeding diseases, ongoing or active infection, or significant cardiac or psychological conditions), and/or substance abuse which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol.
  2. History of another primary except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence (per investigator assessment). Exceptions include adequately resected non-melanoma skin cancer (basal cell carcinoma of the skin or squamous cell carcinoma of the skin) and curatively treated in situ disease.
  3. Persistent toxicities caused by previous anti-cancer therapy, excluding alopecia, not yet improved to Grade ≤ 1 or baseline. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the investigator may be included (eg, hearing loss).
  4. Uncontrolled infection requiring IV antibiotics, antivirals or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections (participants with localised fungal infections of skin or nails are eligible).
  5. Known active or uncontrolled or C virus infection.
  6. Known (HIV) infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA, cluster of differentiation (CD)4+ count > 350 cells/mm3, no history of an acquired immune deficiency syndrome-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications.
  7. Uncontrolled or significant cardiac disease including:

    • Myocardial infarction or uncontrolled/unstable angina within 6 months prior to Cycle 1 Day 1
    • Congestive heart failure ( Class II to IV), or
    • Uncontrolled or significant cardiac arrhythmia, or
    • Uncontrolled hypertension (resting systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg).
  8. Resting with clinically abnormal findings.
  9. Uncontrolled hypercalcaemia: > 1.5 mmol/L (> 6 mg/dL) ionised calcium, or serum calcium (uncorrected for albumin) > 3 mmol/L (> 12 mg/dL), or corrected serum calcium > , or (symptomatic) hypercalcaemia.
  10. History of non-infectious ILD/pneumonitis that required , has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
  11. Has severe pulmonary function compromise.
  12. .
  13. Clinically significant corneal disease.
  14. Known active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).

    Prior/Concomitant Therapy

  15. Prior exposure to:

    • Any treatment (including ADC) containing a chemotherapeutic agent targeting topoisomerase I
    • TROP2-targeted therapy
    • Prior treatment with same ICC agent
    • Chloroquine/hydroxychloroquine without an adequate treatment of > 14 days prior to randomisation.
  16. Any concurrent anti cancer treatment.
  17. Concurrent use of systemic hormone replacement therapy (HRT; eg, oestrogen and progesterone). However, concurrent use of hormones for other non-cancer-related conditions (eg, insulin for diabetes or levothyroxine for hypothyroidism) is acceptable.
  18. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 3 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
  19. Receipt of live, attenuated vaccine within 30 days prior to the first dose of study treatment.
  20. Concomitant use of chronic systemic (IV or oral) corticosteroids or other medications except for managing AEs (inhaled steroids or intra articular steroid injections are permitted in this study).

    Prior/Concurrent Clinical Study Experience

  21. Previous randomisation in the present study.
  22. Participation in another clinical study with a study intervention or medicinal device administered in the last 4 weeks prior to first dose of study intervention (unless the safety profile is known prior to randomisation), randomisation into a prior T-DXd or Dato DXd study regardless of treatment assignment, or concurrent enrolment in another clinical study, unless it is an observational (non interventional) clinical study or during the follow-up period of an interventional study.
  23. Participants with a known history of severe reactions to either the drug or any (including but not limited to polysorbate 80) of Dato-DXd or ICC.
  24. Known history of severe hypersensitivity reactions to other monoclonal antibodies.

    Other Exclusions

  25. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  26. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.
  27. Currently pregnant (confirmed with positive pregnancy test) or breast feeding or planning to become pregnant.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
644 participants (actual)

Study arms

  • Experimental
    Dato-DXd

    Arm 1: Dato-DXd

    Drug: Dato-DXd

  • Active comparator
    Investigator's Choice of Chemotherapy (ICC)

    Arm 2: If no prior taxane, or prior taxane in the (neo)adjuvant setting and DFI \> 12 months, paclitaxel or nab-paclitaxel If prior taxane and DFI ≤ 12 months: capecitabine, carboplatin, or eribulin.

    Drug: Paclitaxel · Drug: Nab-paclitaxel · Drug: Carboplatin · Drug: Capecitabine · Drug: Eribulin mesylate

Interventions

  • Experimental drug. Provided in 100mg vials. IV infusion.

    Also known as: Datopotamab deruxtecan (Dato-DXd, DS-1062a)

  • IV Infusion. Active comparator

  • IV infusion. Active comparator

  • IV infusion. Active comparator

  • Tablet. Oral route of administration. Active comparator

  • IV infusion. Active comparator

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression. However, if the participant progresses or dies immediately after 2 or more consecutive missed visits, the participant will be censored at the time of the latest evaluable assessment prior to the 2 missed visits. The measure of interest is the hazard ratio \[HR\] of PFS.

    Time frame: From randomization until progression as assessed by BICR or death due to any cause (anticipated to be up to 26 months)

  2. Overall Survival (OS)

    OS is defined as the time from randomisation until the date of death due to any cause. The analysis will include all randomised participants, by treatment group as randomised. The measure of interest is the hazard ratio \[HR\] of OS.

    Time frame: From randomisation until the date of death due to any cause (approximately 42 months)

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants who have a confirmed CR or PR, as determined by BICR/investigator assessment, per RECIST 1.1. The analysis will include all randomised participants, by treatment group as randomised. Data obtained from randomisation up until progression, or the last evaluable assessment in the absence of progression, will be included in the assessment of ORR, regardless of whether the participant withdraws from therapy. Participants who go off treatment without a response or progression, receive a subsequent anti-cancer therapy, and then respond will not be included as responders in the ORR. The measure of interest is the odds ratio of the ORR.

    Time frame: From randomisation up until progression (anticipated to be up to 26 months)

  2. Duration of Response (DoR)

    DoR is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause. The analysis will include all randomised participants as randomised who have a confirmed response, regardless of whether the participant withdraws from therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression. The measure of interest is the median of DoR,

    Time frame: From the date of first documented confirmed response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause (anticipated to be up to 26 months)

  3. Progression-Free Survival (PFS) by Investigator assessment

    PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression. The measure of interest is the hazard ratio \[HR\] of PFS.

    Time frame: From randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause (anticipated to be up to 26 months)

  4. Disease Control Rate (DCR)

    DCR at 12 weeks is defined as the percentage of participants who have a confirmed CR or PR or who have SD, per RECIST 1.1, as assessed by BICR/investigator assessment and derived from the raw tumour data for at least 11 weeks after randomisation. The analysis will include all randomised participants by treatment group as randomised. Data obtained from randomisation up until progression, or the last evaluable assessment in the absence of progression, will be included in the assessment of DCR, regardless of whether the participant withdraws from therapy. Participants who receive a subsequent anticancer therapy prior to Week 11 will not be considered to have disease control in the analysis. The measure of interest is the odds ratio of the DCR.

    Time frame: At least 11 weeks after randomization to 23 months

  5. Time to deterioration (TTD) in pain in participants treated with Dato DXd compared with ICC

    TTD in pain as measured by the pain scale from EORTC IL146. TTD is defined as time from the date of randomisation to the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analysis will include all randomised participants. The measure of interest is the hazard ratio \[HR\] of TTD in pain.

    Time frame: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression)

  6. Time to deterioration (TTD) in physical functioning in participants treated with Dato DXd compared with ICC

    TTD in physical functioning as measured by the physical functioning scale from EORTC IL146. TTD is defined as time from the date of randomisation to the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analysis will include all randomised participants. The measure of interest is the hazard ratio \[HR\] of TTD in physical functioning.

    Time frame: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression)

  7. Time to deterioration (TTD) in breast and arm symptoms in participants treated with Dato DXd compared to ICC

    * TTD in breast symptoms as measured by the breast symptoms scale from EORTC IL116 * TTD in arm symptoms as measured by the arm symptoms scale from EORTC IL116 TTD is defined as time from the date of randomisation to the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analysis will include all randomised participants. The measure of interest is the hazard ratio \[HR\] of TTD in breast symptoms/arm symptoms.

    Time frame: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression)

  8. Time to deterioration (TTD) in GHS/QoL in participants treated with Dato DXd compared with ICC

    TTD in GHS/QoL as measured by the GHS/QoL scale from EORTC IL146. TTD is defined as time from the date of randomisation to the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analysis will include all randomised participants. The measure of interest is the hazard ratio \[HR\] of TTD in GHS/QoL.

    Time frame: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression)

  9. Time to First Subsequent Therapy (TFST)

    TFST is defined as the time from randomisation until the start date of the first subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause. The analysis will include all randomised participants as randomised, regardless of progression status. The measure of interest is the hazard ratio \[HR\] of TFST.

    Time frame: From randomisation until the start date of the first subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause (anticipated to be up to 26 months)

  10. Time to Second Subsequent Therapy (TSST)

    TSST is defined as the time from randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause. The analysis will include all randomised participants as randomised, regardless of progression status on study treatment or first subsequent treatment. The measure of interest is the hazard ratio \[HR\] of TSST.

    Time frame: From randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (anticipated to be up to 26 months)

  11. Progression Free Survival 2 (PFS2)

    PFS2 will be defined as the time from randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death. The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard clinical practice. The analysis will include all randomised participants as randomised regardless of whether the participant withdraws from subsequent therapy and regardless of missed visits. The measure of interest is the hazard ratio \[HR\] of PFS2.

    Time frame: From randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death (anticipated to be up to 26 months)

  12. Pharmacokinetics of Dato-DXd

    Concentration of Dato DXd, total anti-TROP2 antibody, and MAAA-1181a in plasma.

    Time frame: From first dose to end of treatment (anticipated to be up to 26 months)

  13. Immunogenicity of Dato-DXd

    Presence of ADAs for Dato-DXd (confirmatory results: positive or negative, titres).

    Time frame: From first dose to end of treatment safety follow-up (anticipated to be up to 26 months)

  14. Safety of Dato-DXd

    Safety will be evaluated in terms of AEs (graded by CTCAE version 5.0)

    Time frame: From first dose to end of treatment safety follow-up (anticipated to be up to 26 months)

07

Study locations

228 sites
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Los Angeles, California 90017, United States
  • Research Site
    San Francisco, California 94143, United States
  • Research Site
    Grand Junction, Colorado 81501, United States
  • Research Site
    Longmont, Colorado 80504, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Washington D.C., District of Columbia 20010, United States
  • Research Site
    Miami, Florida 33170, United States
  • Research Site
    Miami, Florida 33176, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Louisville, Kentucky 40207, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Albuquerque, New Mexico 87109, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Providence, Rhode Island 02903, United States
  • Research Site
    Sioux Falls, South Dakota 57105, United States
  • Research Site
    Memphis, Tennessee 38120, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Kingwood, Texas 77339, United States
  • Research Site
    San Antonio, Texas 78240, United States
  • Research Site
    Charlottesville, Virginia 22908, United States
  • Research Site
    Spokane Valley, Washington 99216, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Buenos Aires, 1058, Argentina
  • Research Site
    CABA, 1414, Argentina
  • Research Site
    CABA, 1426, Argentina
  • Research Site
    CABA, C1113AAE, Argentina
  • Research Site
    Ciudad Autónoma Buenos Aires, C1430EFA, Argentina
  • Research Site
    Ciudad de Buenos Aires, 1426, Argentina
  • Research Site
    Mar del Plata, B7600, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    Anderlecht, 1070, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Namur, 5000, Belgium
  • Research Site
    Sint-Niklaas, 9100, Belgium
  • Research Site
    Wilrijk, 2610, Belgium
  • Research Site
    Brasília, 71681-603, Brazil
  • Research Site
    Curitiba, 80440-220, Brazil
  • Research Site
    Goiânia, 74000-000, Brazil
  • Research Site
    Jaú, 17210-120, Brazil
  • Research Site
    Porto Alegre, 90619-900, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Rio de Janeiro, 20560-120, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    São Paulo, 01321-001, Brazil
  • Research Site
    São Paulo, 01409-001, Brazil
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
  • Research Site
    Barrie, Ontario L4M 6M2, Canada
  • Research Site
    Hamilton, Ontario L8V 5C2, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Québec, Quebec G1S 4L8, Canada
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100039, China
  • Research Site
    Beijing, 100044, China
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610000, China
  • Research Site
    Chongqing, 400016, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Hefei, 230031, China
  • Research Site
    Hefei, 230601, China
  • Research Site
    Jinan, 250001, China
  • Research Site
    Jinan, 2501117, China
  • Research Site
    Nanchang, 330009, China
  • Research Site
    Nanjing, 210036, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 201318, China
  • Research Site
    Shenyang, 110042, China
  • Research Site
    Shenzhen, 518020, China
  • Research Site
    Tianjin, 300000, China
  • Research Site
    Xi'an, 710004, China
  • Research Site
    Xi'an, 710100, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Zhengzhou, 450052, China
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    Limoges, 87042, France
  • Research Site
    Lyon, 69373, France
  • Research Site
    Marseille, 13273, France
  • Research Site
    Montpellier, 34298, France
  • Research Site
    Paris, 75010, France
  • Research Site
    Rouen, 76021, France
  • Research Site
    Saint-Herblain, 44805, France
  • Research Site
    Tours, 37000, France
  • Research Site
    Aschaffenburg, 63739, Germany
  • Research Site
    Bonn, 53111, Germany
  • Research Site
    Frankfurt am Main, 60431, Germany

Showing the first 100 of 228 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Dent RA, Cescon DW, Bachelot T, Jung KH, Shao ZM, Saji S, Traina TA, Vukovic P, Mapiye D, Maxwell MJ, Schmid P, Cortes J. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol. 2023 Nov;19(35):2349-2359. doi: 10.2217/fon-2023-0228. Epub 2023 Aug 1. PubMed 37526149 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Aug 2025, 39 months.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 39 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2022
First posted
May 16, 2022
StartActual
May 16, 2022
Primary completionActual
Aug 25, 2025
CompletionEst.
Dec 31, 2026
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05374512
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
May 16, 2022
Start date
May 16, 2022
Primary completion
Aug 25, 2025
Completion
Dec 31, 2026 (estimated)
Last update
May 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Datopotamab deruxtecan

Start the discussion